Virax Biolabs Group Ltd

Virax Biolabs Group Ltd. is a holding company. It engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.

Earnings data Q2 2024

Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.

LONDON and DUBAI, UAE, July 18, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has signed contracts to launch two new research and laboratory facilities in the United Kingdom. The Company has signed a contract to launch a laboratory facility at Scale Space.

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

ATI Physical Therapy

Bit Digital, Inc

Matterport

In the dynamic world of investing, information is power. For those navigating the high-risk, high-reward landscape of penny stocks, staying abreast of news headlines and company updates is not just a strategy—it's a necessity.

Penny Stocks To Buy? 4 To Watch With Breaking News

LONDON and DUBAI, UAE, May 4, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it established a regional headquarters at Dubai Science Park, a member of TECOM Group PJSC. The office space is located in the heart of the global science-focused community that enables research, innovation and businesses in the health, energy, life sciences and environment sectors.

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

Virax Biolabs (NASDAQ: VRAX ) stock is on the rise Wednesday after the company secured a PCR test distribution deal. This covers the Marburg Virus Real Time PCR Kit.

Virax Biolabs (VRAX) Stock Soars on PCR Test DIstribution Agreement

LONDON , April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits. The Marburg Virus Real Time PCR Kit is an in-vitro diagnostic test, based on real-time PCR technology, for the detection of ribonucleic acid (better known as RNA) from the Marburg Virus.

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

LONDON , March 10, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the closing of its previously announced private placement of 3,843,309 ordinary shares (or ordinary share equivalents), Series A preferred investment options to purchase up to an aggregate of 3,497,412 ordinary shares and Series B preferred investment options to purchase up to an aggregate of 3,843,309 ordinary shares at a purchase price of $1.04077 per ordinary share and associated preferred investment options priced at the market under Nasdaq rules. The Series A preferred investment options have an exercise price of $0.80202 per ordinary share and are exercisable immediately for a period of five and a half years.

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LONDON , March 8, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into definitive agreements for the purchase and sale of 3,843,309 ordinary shares (or ordinary share equivalents), Series A preferred investment options to purchase up to an aggregate of 3,497,412 ordinary shares and Series B preferred investment options to purchase up to an aggregate of 3,843,309 ordinary shares at a purchase price of $1.04077 per ordinary share and associated preferred investment options in a private placement priced at the market under Nasdaq rules. The Series A preferred investment options have an exercise price of $0.80202 per ordinary share and will be exercisable immediately upon issuance for a period of five and a half years from the date of issuance.

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Troika Media Group

Unicycive Therapeutics

What you need to know about day trading penny stocks The post Penny Stocks Investing: The Pros and Cons of Day Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Investing: The Pros and Cons of Day Trading

What has financial traders so excited about Virax Biolabs (NASDAQ: VRAX ) today? In a fresh press release, Virax Biolabs disclosed a testing kit for the disease commonly known as avian flu or bird flu.

Why Is Virax Biolabs (VRAX) Stock Up 100% Today?

LONDON , March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus ("AIV") real-time PCR test kit to markets accepting the CE mark, namely the European Union. The test kit is for the detection and differentiation of ribonucleic acid from AIV and the H5, H7 and H9 subtypes, including the H5N1 strain currently spreading in Europe.

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Boxlight

Grove Collaborative Holdings

Imperial Petroleum

IronNet

Spectrum Pharma

VIQ Solutions

GeneDx Holdings Corp

Wearable Devices Ltd

Penny stocks under $1 to watch this month. The post 10 Top Penny Stocks Under $1 To Watch For February 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks Under $1 To Watch For February 2023

Iveda Solutions Inc

$1 penny stocks to watch right now. The post 7 Hot Penny Stocks Under $1 To Watch For February 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1 To Watch For February 2023

Cosmos Holdings

CHICAGO, IL / ACCESSWIRE / February 7, 2023 / Cosmos Health Inc. ("the Company") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the first purchase order to market and distribute Virax Biolabs' (Nasdaq: VRAX) ViraxClear branded COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to its previously signed distribution agreement dated September 2022, Cosmos Health will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

LONDON , Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to their previously signed distribution agreement dated September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

LONDON , Feb. 6, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Dr. Tomasz George, Chief Scientific Officer of Virax, and Cameron Shaw, Chief Operations Officer at Virax, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 7, 2023. The presentation will highlight the recent Company developments, anticipated milestones and ongoing clinical and business developments.

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Kit Available Now for Distribution LONDON , Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Kits available Now for Distribution LONDON , Dec. 6, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that their supplier has received an Emergency Use Authorization ("EUA") from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test (the "Test"). The Tests are ready for sale in the US by Virax.

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

LONDON , Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.  "We are thrilled to welcome Richard to our team," said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs.

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

LONDON , Nov. 8, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the closing of its previously announced private placement of 2,330,000 ordinary shares (or ordinary shares equivalents in lieu thereof) at a gross purchase price of $1.65 per share. Additionally, as part of the transaction, Virax has issued unregistered warrants to purchase up to 3,495,000 ordinary shares (the "Ordinary Warrants").

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

LONDON , Nov. 4, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 2,330,000 shares of ordinary shares (or ordinary shares equivalents in lieu thereof) at a gross purchase price of $1.65 per share. Additionally, Virax has agreed to issue to the investor unregistered warrants to purchase up to 3,495,000 shares of ordinary shares (the "Ordinary Warrants").

Virax Biolabs Group Limited Announces $3.8 Million Private Placement

Ambev

Transocean

Tellurian

Are you making these beginner penny stocks trading mistakes? The post Biggest Beginner Penny Stocks Trading Mistakes?

Biggest Beginner Penny Stocks Trading Mistakes? 3 to Know

Small-cap business Virax Biolabs (NASDAQ: VRAX ) isn't often in the headlines, but today is a special day for the company. Reportedly, Virax's new rapid testing kit is a triple-threat.

Why Is Virax (VRAX) Stock Up 40% Today?

Kits available in November for Distribution LONDON , Nov. 3, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in both at-home and in point-of-care settings to accurately identify infections related to respiratory syncytial virus (RSV), influenza and COVID-19 with results typically available in 15 minutes.

Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit

LONDON , Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year. The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit and will include specimens from 96 healthy volunteers1.

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Exclusive distribution agreement signed with Cosmos Holdings Inc. (Nasdaq: COSM), providing for exclusive distribution rights in Greece and Cyrus with the opportunity for Cosmos to distribute across Europe on a non-exclusive basis. LONDON , Sept.

News for Virax Biolabs Group Ltd Stock (VRAX)